Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin

Molecular Medicine Reports

Volumn 6, Issue 6, 2012, Pages 1351-1354

  Jiang, Shan ^a   Chen, Xiaopin ^a   Li, Chunyan ^a   Zhang, Xingping ^a   Zhang, Tao ^a   Yue, Yujuan ^a   Yang, Guang ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Growth; Nasopharyngeal carcinoma; Osteopontin; Suramin

Indexed keywords

BETA ACTIN; OSTEOPONTIN; PROTEIN KINASE B; SURAMIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; FLOW CYTOMETRY; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; NASOPHARYNGEAL NEOPLASMS; OSTEOPONTIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; S PHASE CELL CYCLE CHECKPOINTS; SURAMIN;

EID: 84868561310     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1074     Document Type: Article

References (20)

1. Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777, 2006. (Pubitemid 44664247)
2. Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol 20: 264-269, 2008.
3. Hawking F: Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother 15: 289-322, 1978.
4. Song S, Yu B, Wei Y, Wientjes MG and Au JL: Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 10: 6058-6065, 2004. (Pubitemid 39287510)
5. Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ and Hotz HG: Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg 11: 171-178, 2007.
6. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, et al: A phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer 100: 65-71, 2004. (Pubitemid 37553540)
7. Agrawal D, Chen T, Irby R, et al : Osteopontin identified as lead marker of colon cancer progression using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521, 2002. (Pubitemid 34411290)
8. Rudland PS, Platt-Higgins A, El-Tanani M, et al : Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427, 2002. (Pubitemid 34651388)
9. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004. (Pubitemid 38114178)
10. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L: Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55: 483-90, 2012.
11. Gong M, Lu Z, Fang G, Bi J and Xue X: A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 272: 148-159, 2008.
12. Geissinger E, Weisser C, Fischer P, Schartl M and Wellbrock C: Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 62: 4820-4828, 2002.
13. Yang G, Zhang Y, Wu J, Xiong J, Deng H, Wang J, Yang C and Zhu Z: Osteopontin regulates growth and migration of human nasopharyngeal cancer cells. Mol Med Rep 4: 1169-1173, 2011.
14. Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL and Yuen AP: Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 31: 555-558, 2005. (Pubitemid 40724099)
15. Hui EP, Sung FL, Yu BK, et al: Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res 14: 7080-7087, 2008.
16. McCain DF, Wu L, Nickel P, Kassack MU, Kreimeyer A, Gagliardi A, Collins DC and Zhang ZY: Suramin derivatives as Inhibitors and activators of protein-tyrosine phosphatases. J Biol Chem 279: 14713-14725, 2004. (Pubitemid 38618861)
17. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H and Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300, 1996. (Pubitemid 26023348)
18. Kolfschoten GM, Hulscher TM, Pinedo HM and Boven E: Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer 83: 921-927, 2000.
19. Zhang G, He B and Weber GF: Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 23: 6507-6519, 2003. (Pubitemid 37075762)
20. Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES and Lee SH: Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells. Cancer Res 65: 686-691, 2005. (Pubitemid 40216422)